Circulating Endothelial Progenitor Cells is a predictor in Atherosclerosis: Is it really a promising candle?

Anwar Santoso

doi:10.30701/ijc.v34i1.300

Anwar Santoso Dept. of Cardiology–Vascular Medicine, School of Medicine – University of Indonesia, National Cardiovascular Centre, Harapan Kita Hospital, Jakarta.

DOI: https://doi.org/10.30701/ijc.v34i1.300

Abstract

Circulating endothelial progenitor cells (CEPC) are supposed to be a subset of bone marrow-derived peripheral blood mononuclear cells (PBMC), revealing immature surface markers common to hematopoietic stem cells, such as CD 34 and CD 133 and endothelial lineage markers. These cells can be isolated from peripheral, umbilical cord, and bone marrow blood. CD 34 represents a marker of immature stem cells that is commonly used to characterize CEPC together with other surface antigens. Though, as CD 34 is also expressed at lower levels on mature endothelial cells, most recent studies used CD 133, a marker of more immature hematopoietic stem cells that is now considered the best surface marker to define, identify and isolate the CEPC1. CD 133 (also known as AC 133 or prominin) is highly conserved antigen with unknown biological activity. It would be expressed on hematopoietic stem cells, but not on mature endothelial cell and monocytes. In order to reflect the endothelial cells, there is general agreement for the use of at least one additional marker, such as vascular endothelial growth factor receptor-2 (VEGFR-2 or KDR), while others are platelet-endothelial cells adhesion molecules-1 (PECAM-1), von Willebrand factor, c-kit, Tie-2, vascular endothelial-cadherin and VEGFR-12.

Downloads

Download data is not yet available.

References

Fadini GP, Agostini C, Avogaro A. Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspective. Curr Diabetes Review 2005;1:41 – 58.

Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95(4): 343-53.

Shantsila E, Watson T, Lip GYH. Endothelial Progenitor Cells in Cardiovascular Disorders. J Am Coll Cardiol 2007;49(7): 741-52.

Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases: a statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-46.

Chen JZ, Zhang FR, Tao QM, et al. Number andactivity of endothelial progenitor cells from peripheral blood inpatients with hypercholesterolaemia. Clin Sci (Lond) 2004;107:273-80.

Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascularendothelial growth factor-induced proliferation and network formationof endothelial progenitor cells. Hypertens Res 2004;27:101- 8.

Obi S, Masuda H, Shizuno T, et al. Fluid shear stress induces differentiation of circulating phenotype progenitor cells. Am J Physiol Cell Physiol 2012;303:C595-C606.

Saito H, Yamamoto Y, Yamamoto H. Diabetes alters subsets of endothelial cells that reside in blood, bone marrow, and spleen. Am J Physiol Cell Physiol 2012;302:C892-C901.

Krankel N, Adams V, Linke A, et al. Hyperglycemia reduces
Jurnal Kardiologi Indonesia
22
Jurnal Kardiologi Indonesia • Vol. 34, No. 1 • Januari - Maret 2013
survivaland impairs function of circulating blood-derived progenitor cells.Arterioscler Thromb Vasc Biol 2005;25:698 –703.

Nurwidyaningtyas W, Sargowo D, Agoes A, Andri TW, Satuman. J Kardiol Indones. 2013;34:14-9.

Rabelink TJ, de Boer HC, de Koning EJ, et al. Endothelial progenitor cells: more than an inflammatory response? Arterioscler Thromb Vasc Biol 2004;24(5):834-8.